Use of selective serotonin reuptake inhibitors and other serotonergic drugs in the biological dissection of affective disorders.
The need to subtype patients with affective disorders on the basis of biological characteristics is well recognized, and much of the research in this area has focused on the serotonergic system. Biological subtyping can be approached using both peripheral and central markers. Peripheral markers include platelet serotonin concentrations, the density and affinity of platelet serotonin reuptake and platelet 5-HT2 receptors, and plasma serotonin concentrations. Central markers include cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA) concentrations, and endocrine, psychological and body temperature responses to challenge tests with a number of serotonergic drugs. More recently, the role of selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs in sleep, and in the control of cardiovascular homeostasis, has been studied. This may provide a greater understanding of the mechanisms of serotonin dysregulation in affective disorders, and may ultimately improve treatment of these conditions.
Nutt
D J
DJ
Psychopharmacology Unit, School of Medical Sciences, Bristol, UK.
Wilson
S J
SJ
Coupland
N J
NJ
D015415:Biomarkers; D001794:Blood Pressure / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy; D016666:Fluvoxamine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008094:Lithium / Q000494:pharmacology; D008127:Lofepramine / Q000494:pharmacology; D019964:Mood Disorders / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012893:Sleep Wake Disorders; D013997:Time Factors
D015415:Biomarkers; D016666:Fluvoxamine; D008094:Lithium; D008127:Lofepramine; D017367:Selective Serotonin Reuptake Inhibitors